Lecanemab for Alzheimer's disease

BMJ. 2022 Dec 19:379:o3010. doi: 10.1136/bmj.o3010.

Authors

Sebastian Walsh¹, Richard Merrick¹, Edo Richard^{2

3}, Shirley Nurock⁴, Carol Brayne¹

Affiliations

¹ Cambridge Public Health, University of Cambridge, Cambridge, UK.
² Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, Netherlands.
³ Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
⁴ London, UK.

PMID: 36535691
DOI: 10.1136/bmj.o3010

No abstract available

Publication types

Editorial

MeSH terms

Alzheimer Disease*
Humans

Substances

lecanemab